HPTN 084 Qualitative Substudy Funding

Investigator: Zvavahera Chirenje, MD, FRCOG
Sponsor: FHI 360

Location(s): Kenya; Malawi; Uganda; Zimbabwe; Botswana; South Africa; Swaziland


HPTN 084 (The LIFE Study) is a study being done to evaluate the safety and efficacy of the injectable agent, cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

Who is participating in the study?

HPTN 084 will enroll approximately 3,200 women 18 to 45 years old in sub-Saharan Africa who are at risk for acquiring HIV.

Why is HPTN 084 important?

PrEP agents are needed that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.